Menu Search
Equities

Dr Reddy's Laboratories Ltd

RDDA:DEU

Dr Reddy's Laboratories Ltd

Actions
  • Price (EUR)13.50
  • Today's Change0.20 / 1.50%
  • Shares traded0.00
  • 1 Year change+9.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Dr Reddy's Laboratories Ltd grew revenues 13.54% from 245.88bn to 279.16bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 23.56% net income growth from 45.07bn to 55.68bn.
Gross margin59.29%
Net profit margin18.07%
Operating margin22.58%
Return on assets13.33%
Return on equity19.10%
Return on investment18.20%
More ▼

Cash flow in INRView more

In 2024, Dr Reddy's Laboratories Ltd increased its cash reserves by 22.98%, or 1.33bn. The company earned 45.43bn from its operations for a Cash Flow Margin of 16.27%. In addition the company used 40.28bn on investing activities and also paid 3.76bn in financing cash flows.
Cash flow per share0.9868
Price/Cash flow per share14.55
Book value per share4.34
Tangible book value per share2.86
More ▼

Balance sheet in INRView more

Dr Reddy's Laboratories Ltd has a Debt to Total Capital ratio of 13.57%, a higher figure than the previous year's 2.39%.
Current ratio1.92
Quick ratio1.34
Total debt/total equity0.159
Total debt/total capital0.1357
More ▼

Growth rates in INR

SmartText is unavailable
Div yield(5 year avg)0.63%
Div growth rate (5 year)14.77%
Payout ratio (TTM)12.54%
EPS growth(5 years)24.18
EPS (TTM) vs
TTM 1 year ago		4.67
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.